The Asia Pacific Biodefense Market would witness market growth of 7% CAGR during the forecast period (2020-2026). Biodefense is considered as the steps taken to re-establish the biosecurity of a group of organisms that are confronting biological threats or infectious diseases. It refers to an efficient public health care system with robust disease surveillance and quick actions designed to manage biological threats, to prevent the spread of disease, and offer medical care. The rising threat of biological weapons & nuclear-armed ICBM, supportive governmental initiatives, and expansion in the naturally occurring outbreaks, are leading factors pushing the market growth. Although, low investment in R&D by the government in emerging and underdeveloped countries, is anticipated to hamper the development of the biodefense market during the forecast years.
The advancements in technology have encouraged the innovation of advanced biosensor technology that is able to check both pathogens and benign microorganisms. In addition, various agencies are striving to create multifunctional sensors. Biotechnology provides an opportunity for the development of efficient countermeasures to biological weapons. Development and manufacturing of vaccines are of utmost importance from a biosecurity outlook.
The biodefense market will witness developmental possibilities if the government undertakes constant preventive steps to ensure the safety of the population and the economy. As the governments invest in these current and future policy initiatives, the companies operating in the market will witness a significant push in their revenue streams, by understanding the existing biosecurity and biodefense policy.
Based on Product, the market is segmented into Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: Biodefense Market in Asia Pacific is expected to register a CAGR of 7% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Anthrax
- Smallpox
- Botulism
- Radiation/nuclear
- Other Products
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Companies Profiled
- Xoma Corporation
- Altimmune, Inc.
- Emergent BioSolutions, Inc.
- Dynavax Technologies Corporation
- SIGA Technologies, Inc.
- Elusys Therapeutics, Inc.
- Ichor Holdings, Ltd.
- Cleveland BioLabs, Inc.
- Bavarian Nordic A/S
- Alnylam Pharmaceuticals, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Biodefense Market, by Product
1.4.2 Asia Pacific Biodefense Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Recent Industry Wide Strategic Developments
3.1.1 Partnerships, Collaborations and Agreements
3.1.2 Approvals
3.1.3 Acquisition and Mergers
3.2 Top Winning Strategies
3.2.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.2.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Jul – 2020, Jul) Leading Players
Chapter 4. Asia Pacific Biodefense Market by Product
4.1 Asia Pacific Anthrax Market by Country
4.2 Asia Pacific Smallpox Market by Country
4.3 Asia Pacific Botulism Market by Country
4.4 Asia Pacific Radiation/nuclear Market by Country
4.5 Asia Pacific Other Product Market by Country
Chapter 5. Asia Pacific Biodefense Market by Country
5.1 China Biodefense Market
5.1.1 China Biodefense Market by Product
5.2 Japan Biodefense Market
5.2.1 Japan Biodefense Market by Product
5.3 India Biodefense Market
5.3.1 India Biodefense Market by Product
5.4 South Korea Biodefense Market
5.4.1 South Korea Biodefense Market by Product
5.5 Singapore Biodefense Market
5.5.1 Singapore Biodefense Market by Product
5.6 Malaysia Biodefense Market
5.6.1 Malaysia Biodefense Market by Product
5.7 Rest of Asia Pacific Biodefense Market
5.7.1 Rest of Asia Pacific Biodefense Market by Product
Chapter 6. Company Profiles
6.1 Xoma Corporation
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expense
6.2 Altimmune, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Research & Development Expense
6.2.4 Recent strategies and developments:
6.2.4.1 Acquisition and Mergers:
6.2.4.2 Partnerships, Collaborations, and Agreements:
6.3 Emergent BioSolutions, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Research & Development Expense
6.3.4 Recent strategies and developments:
6.3.4.1 Acquisition and Mergers:
6.3.4.2 Partnerships, Collaborations, and Agreements:
6.4 Dynavax Technologies Corporation
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Research & Development Expense
6.5 SIGA Technologies, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Research & Development Expense
6.5.4 Recent strategies and developments:
6.5.4.1 Partnerships, Collaborations, and Agreements:
6.5.4.2 Approvals:
6.6 Elusys Therapeutics, Inc.
6.6.1 Company Overview
6.6.2 Recent strategies and developments:
6.6.2.1 Approvals:
6.7 Ichor Holdings, Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Partnerships, Collaborations, and Agreements:
6.8 Cleveland BioLabs, Inc.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expense
6.8.4 Recent strategies and developments:
6.8.4.1 Partnerships, Collaborations, and Agreements:
6.9 Bavarian Nordic A/S
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Partnerships, Collaborations, and Agreements:
6.9.5.2 Approvals:
6.10. Alnylam Pharmaceuticals, Inc.
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Research & Development Expense
TABLE 1 Asia Pacific Biodefense Market, 2016 - 2019, USD Million
TABLE 2 Asia Pacific Biodefense Market, 2020 - 2026, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Bio-defense Market
TABLE 4 Approvals– Bio-defense Market
TABLE 5 Acquisition and Mergers– Bio-defense Market
TABLE 6 Asia Pacific Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 7 Asia Pacific Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 8 Asia Pacific Anthrax Market by Country, 2016 - 2019, USD Million
TABLE 9 Asia Pacific Anthrax Market by Country, 2020 - 2026, USD Million
TABLE 10 Asia Pacific Smallpox Market by Country, 2016 - 2019, USD Million
TABLE 11 Asia Pacific Smallpox Market by Country, 2020 - 2026, USD Million
TABLE 12 Asia Pacific Botulism Market by Country, 2016 - 2019, USD Million
TABLE 13 Asia Pacific Botulism Market by Country, 2020 - 2026, USD Million
TABLE 14 Asia Pacific Radiation/nuclear Market by Country, 2016 - 2019, USD Million
TABLE 15 Asia Pacific Radiation/nuclear Market by Country, 2020 - 2026, USD Million
TABLE 16 Asia Pacific Other Product Market by Country, 2016 - 2019, USD Million
TABLE 17 Asia Pacific Other Product Market by Country, 2020 - 2026, USD Million
TABLE 18 Asia Pacific Biodefense Market by Country, 2016 - 2019, USD Million
TABLE 19 Asia Pacific Biodefense Market by Country, 2020 - 2026, USD Million
TABLE 20 China Biodefense Market, 2016 - 2019, USD Million
TABLE 21 China Biodefense Market, 2020 - 2026, USD Million
TABLE 22 China Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 23 China Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 24 Japan Biodefense Market, 2016 - 2019, USD Million
TABLE 25 Japan Biodefense Market, 2020 - 2026, USD Million
TABLE 26 Japan Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 27 Japan Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 28 India Biodefense Market, 2016 - 2019, USD Million
TABLE 29 India Biodefense Market, 2020 - 2026, USD Million
TABLE 30 India Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 31 India Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 32 South Korea Biodefense Market, 2016 - 2019, USD Million
TABLE 33 South Korea Biodefense Market, 2020 - 2026, USD Million
TABLE 34 South Korea Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 35 South Korea Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 36 Singapore Biodefense Market, 2016 - 2019, USD Million
TABLE 37 Singapore Biodefense Market, 2020 - 2026, USD Million
TABLE 38 Singapore Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 39 Singapore Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 40 Malaysia Biodefense Market, 2016 - 2019, USD Million
TABLE 41 Malaysia Biodefense Market, 2020 - 2026, USD Million
TABLE 42 Malaysia Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 43 Malaysia Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 44 Rest of Asia Pacific Biodefense Market, 2016 - 2019, USD Million
TABLE 45 Rest of Asia Pacific Biodefense Market, 2020 - 2026, USD Million
TABLE 46 Rest of Asia Pacific Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 47 Rest of Asia Pacific Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 48 Key Information –Xoma Corporation
TABLE 49 Key Information – Altimmune, Inc.
TABLE 50 Key Information – Emergent BioSolutions, Inc.
TABLE 51 Key Information – Dynavax Technologies Corporation
TABLE 52 Key Information – SIGA Technologies, Inc.
TABLE 53 key information – Elusys Therapeutics, Inc.
TABLE 54 key Information – Ichor Holdings, Ltd.
TABLE 55 Key Information – Cleveland BioLabs, Inc.
TABLE 56 key information – Bavarian Nordic A/S
TABLE 57 Key Information – Alnylam Pharmaceuticals, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 Key Leading Strategies: Percentage Distribution (2016-2020)
FIG 3 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Jul – 2020, Jul) Leading Players
FIG 4 Recent strategies and developments: Altimmune, Inc.
FIG 5 Recent strategies and developments: Emergent BioSolutions, Inc.